Advancing the management of HER2-altered NSCLC: Interpreting the latest clinical trial data
touchCONGRESS for touchONCOLOGY and touchRESPIRATORY
Listen to thoracic oncologist Dr. Julia Rotow (USA) review the latest HER2-targeted therapy data for NSCLC from the 2026 ASCO Annual Meeting. Alongside Prof. David Planchard (France) and Dr. Misako Nagasaka (USA), they discuss these findings in the context of evidence presented at recent international congresses and their clinical implications for managing HER2-altered NSCLC.
The experts
Dr. Julia Rotow, Dana-Farber Cancer Institute, Boston, MA, USA
Prof. David Planchard, Institut Gustave Roussy, Paris, France
Dr. Misako Nagasaka…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.